Trimethoprim antibiotic more effective against streptococci than expected

Scientists use the zone of inhibition test to study antibiotic resistance of bacteria. The wafers on the culture medium contain an antibiotic that inhibits growth of sensitive bacteria in their vicinity. Credit: HZI/Bergmann und Nitsche-Schmitz

In less-developed countries, inexpensive and well-tolerated antibiotics for therapy of streptococcal infections are often not available. Scientists of the HZI in Germany have discovered that trimethoprim may provide an option. Contrary to a long-held belief, the bacteria are not generally resistant to this agent. In their latest publication the scientists demonstrated three pathways for the development of resistance—meaning that streptococci can easily become resistant to the antibiotic and pass on this trait quickly.

The common bacterium Streptococcus pyogenes is responsible not only for scarlet fever, a childhood disease presenting with characteristic skin rash, but also for many suppurative infections of the skin. The infection can be associated with serious consequences such as and inflammation of the kidneys. In Germany, physicians usually prescribe penicillin, an antibiotic. In less-developed countries, penicillin is not always an option though. Firstly, penicillin is often not available and secondly, co-infections, i.e. concurrent infections, by another bacterium called Staphylococcus aureus occur and this microorganism is often no longer susceptible to the action of penicillin.

A group of scientists directed by Dr Patric Nitsche-Schmitz of the HZI entered into cooperation with the German National Reference Center for Streptococci in Aachen, Germany, to investigate if the antibiotic trimethoprim can be helpful in these scenarios. Trimethoprim inhibits an enzyme of folic acid metabolism called dihydrofolate reductase, which plays an important role in bacterial growth. Trimethoprim thus prevents bacteria from proliferating in the body. In the past, doctors advised against the use of this medication for treatment of . The underlying reasoning was the wide-spread belief that the bacteria are already resistant to this agent, a misconception, as is becoming increasingly more evident. The reason for this mistake is that early studies used a culture medium that reduces the anti-microbial effect of trimethoprim.

The scientists from Braunschweig investigated samples from infected patients from Germany and India for resistance to trimethoprim. The majority of the samples were sensitive to the agent. "This shows that trimethoprim is indeed effective in many cases of Streptococcus pyogenes infection," Nitsche-Schmitz said.

The focus of his team was also on samples, in which the bacteria failed to respond to the agent. They discovered two types of resistance. "Spontaneous mutations can occur in the gene for dihydrofolate reductase rendering trimethoprim no longer able to attack the changed enzyme, which means it becomes ineffective," Nitsche-Schmitz explained. The team from Braunschweig detected a specific mutation in this gene in many samples, which renders streptococci resistant. In addition, bacteria can transfer copies of changed variants of the dihydrofolate reductase gene to other bacteria. This process called horizontal gene transfer allows resistance to spread very rapidly. The scientists found two genes of this type to be further causes of insensitivity.

The study shows that the antibiotic trimethoprim is a therapeutic option for Streptococcus pyogenes infections in some geographical regions of the world. The frequency of resistance is much lower than previously believed and the medication is inexpensive, stable and effective in Staphylococcus aureus co-infections. "However, it is like a sword that can loose its sharpness quickly," Nitsche-Schmitz said. "We found three causes for the rapid spread of resistance. It is important that , like all antibiotics, is not prescribed without need and that patients take the agent in accordance with the instructions given."

More information: René Bergmann, Mark van der Linden, Gursharan S. Chhatwal and D. Patric Nitsche-Schmitz, Factors that cause trimethoprim resistance in Streptococcus pyogenes, Antimicrobial Agent and Chemotherapy, 2014, DOI: 10.1128/AAC.02282-13

add to favorites email to friend print save as pdf

Related Stories

Common antibiotic can have serious adverse reactions

Oct 11, 2011

trimethoprim-sulfamethoxazole – that has been used since 1968 can cause serious adverse reactions and physicians need to be aware of these in prescribing, states a review in CMAJ (Canadian Medical Association Journal). ...

Emerging antibiotic resistance in Listeria

Jan 24, 2013

Malaysian researchers have revealed the presence of multidrug-resistant strains of Listeria monocytogenes in frozen burger patties taken from supermarkets and other retail shops in Malaysia. The research ...

Chemists discover new class of antibiotics

Mar 07, 2014

(Phys.org) —A team of University of Notre Dame researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments